Short Decsription
Creative Biolabs offers HEK293T-Tg(Human GLP-2 Receptor) Division-Arrested Cell which GLP-2 receptor stably expressed in HEK293T cells.
Description
HEK293T-Tg(Human GLP-2 Receptor) Division-Arrested Cell was engineered to express the receptor human GLP-2 (NM_004382.3). This cell line can be used to study GLP-2 receptor function, signaling pathways, and potential therapeutic interventions. Dividing-arrest cells are cells that are normally kept under specific culture conditions or treated with agents that prevent cell division from being held in a non-dividing state. This can be achieved through methods such as serum starvation, chemical inhibitors of cell cycle progression, or genetic modification.
Features
Well-characterized stable cell lines;
for cell-based high-throughput screening;
Low-cost evaluation of stable cell lines or limited quantities of compounds.
Applications
GLP-2 receptor function, signaling pathways, and potential therapeutic interventions.
Protein Target
GPCR
Receptor Name
GLP-2
Receptor Family
Glucagon
Species
Human
Parental Cell Line
HEK293T
Transfection
Expression vector containing full-length human CRHR1 cDNA (GenBank Accession Number NM_004382.3) with FLAG tag sequence at N-terminus
Gene
NM_004382.3
Background
Glucagon-like peptide 2 receptor belongs to the glucagon-secretin receptor superfamily of GPCRs. The human GLP-2 receptor gene is localized on chromosome 17p13.3. The GLP-2 receptor exhibits ~50% amino acid identity with GLP-1 receptor. GLP-2 receptor binds to Glucagon-like peptide-2 (GLP-2) is a nutrient-responsive hormone and activates adenylate cyclase pathway and to a lesser extent activates MAP kinases. GLP-2 receptors are found in the central nervous system and gastrointestinal tract, with the highest expression levels in jejunum. The principal role of GLP-2 receptors appears to be the maintenance of the growth, nutrient absorption, cell proliferation, apoptosis, mucosal blood flow and suppressing gastric motility and secretion. The regenerative and cytoprotective properties of GLP-2 contribute to its therapeutic potential for the treatment of patients with intestinal disease. Recent studies have suggested that GLP-2 not only modulates intestinal stem cell behavior but may also promote carcinogenesis in models of sporadic colon cancer. Further consideration of the molecular cross-talk and downstream signaling pathways mediating the intestinotropic effects of GLP-2 is important. A detailed delineation of the signaling pathways activated by gut peptide GPCRs, as exemplified by GLP-1and GLP-2, may provide new therapeutic targets for the treatment of human disorders such as diabetes and intestinal disease, respectively

For Research Use Only | Not For Clinical Use

Online Inquiry
Related Products
Copyright © 2024 Creative Biolabs. All Rights Reserved.